Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- GoogleMy eighth-grade students built our school newscast from scratch with Gemini.Companies: Alphabet Inc.Eighth graders built The Cougar Rumble newscast using Gemini and Google Docs. See how these students streamlined their production workflow today.
- Cedarville UniversityOhio's Cedarville University Opening New Florida LocationClearwater Facility Set to Open in January 2027
- SASSAS Championship tees up a week of golf, innovation and community impactFairway to Fun, HBCU Invitational, Women's Day and other signature programs extend the tournament's purpose beyond the course — Championship golf takes center stage Oct. 12-18 as the 2026 SAS Championship returns to Prestonwood Country Club,...
- Once Upon a Farm, PBCOnce Upon a Farm Expands Kids Portfolio With Organic Electrolyte PouchesProviding real-food fuel for the back-to-school season, this expansion solidifies the brand's leadership in organic, simple, nutritious foods for children, addressing growing parental demand for clean snack options across all early childhood stages Download High-Res Product Images Here....
- ChervonChervon Names Claudio Chiappetta Vice President of Retail Sales for Chervon CanadaNAPERVILLE, IL, Oct 5, 2026 - Claudio Chiappetta joins Chervon as Vice President of Retail Sales for Chervon Canada; effective Monday, October 5, 2026, reporting to VP, MD Neil Harrison. A graduate of York University in Toronto, Chiappetta majored in business and marketing. He brings over 25 years of outdoor power equipment and power tool experience to Chervon as well as extensive knowledge of the Canadian home improvement and outdoor power equipment markets. Chiappetta launched his tool and outdoor career in 2003 at Black & Decker/DeWalt where he held various sales and marketing positions including cordless product manager for DeWalt Power Tools. Claudio joined TTI Milwaukee in 2008 where he was responsible for the launch of a series of Milwaukee cordless products into the Canadian market. He went on to build and manage the Ryobi outdoor power equipment portfolio along with multiple TTI power tool brands. "I am delighted to welcome Claudio to our Canadian senior management team," says VP, MD Neil Harrison. "Claudio's outstanding leadership, marketing and customer development skills will serve us well as we build out Chervon Canada." "I very much look forward to working together again with Neil Harrison and Trevor Bithrey in growing Chervon Canada," says Chiappetta. "Chervon's clear commitment to developing Canada's continued growth and success is most exciting." About Chervon Chervon North America is part of a global total solution provider specializing in R&D, manufacturing, testing, sales, and after-sales service of power tools and outdoor power equipment (OPE). Guided by user-centric innovation, the Company operates an integrated business model supported by global sales and distribution networks. Chervon's portfolio includes EGO, FLEX, SKIL, and DEVON, serving industrial, professional, and consumer markets globally. Better Tools. Better World. Chervon is committed to delivering superior products to users worldwide through continuous innovation and strives to become a global leader in power tools and OPE in the lithium-ion, intelligent, and digital era. PR Contact: Corporate Communications: [email protected] SOURCE: Chervon
- Chervon Appoints Neil Harrison to the Position of VP Sales, Marketing and MD for Chervon CanadaNAPERVILLE, IL, Oct 5, 2026 - Neil Harrison joins Chervon as Vice President Sales, Marketing and Managing Director for Chervon Canada; effective Monday, October 5, 2026, reporting to CEO Joe Galli. Harrison brings more than 23 years of professional and consumer power tools experience. After studying environmental research management and graduating of the University of Western Ontario in London, Ontario; Harrison began his tool career in 2003 with Black & Decker/DeWalt, advancing through various positions in sales, operations, and product management. In 2006, Harrison joined Bosch Canada as marketing manager for the SKIL brand. He then went on to a position as an account manager with Hilti Canada. In 2008, Harrison joined TTI/Milwaukee, where he launched an impressive 17-year career advancing through leadership positions in product management, channel management, and marketing management. He went on to lead regional sales teams in the industrial construction channels for Ontario and eastern Canada and also built and managed a national field sales team for the hardware and automotive channels. Most recently, Harrison was the managing director for Klingspor Abrasives Canada where he oversaw the entire Canadian business including sales, marketing, warehouse and operations, human resources, and finance. Throughout his career, Harrison has distinguished himself as a strong leader with a track record for developing exceptional people, brands, customer relationships and growing business units in the Canadian theater. "We are delighted to now have Neil in place as our leader of Chervon Canada, says CEO Joe Galli. Neil's impressive leadership skills, business management skills and customer-centricity make him an ideal candidate to lead our Canadian business." "I can't wait to get started in building and leading our Canadian business unit here at Chervon," said Harrison. "Chervon is clearly making a commitment to developing a leadership Canadian business, and I am enormously grateful to lead this new effort." About Chervon Chervon North America is part of a global total solution provider specializing in R&D, manufacturing, testing, sales, and after-sales service of power tools and outdoor power equipment (OPE). Guided by user-centric innovation, the Company operates an integrated business model supported by global sales and distribution networks. Chervon's portfolio includes EGO, FLEX, SKIL, and DEVON, serving industrial, professional, and consumer markets globally. Better Tools. Better World. Chervon is committed to delivering superior products to users worldwide through continuous innovation and strives to become a global leader in power tools and OPE in the lithium-ion, intelligent, and digital era. PR Contact: Corporate Communications [email protected] SOURCE: Chervon
- ChervonChervon Names Peter J. Carlson Director of Sales for Strategic AccountsNAPERVILLE, IL, Oct 5, 2026 - Peter J. Carlson joins Chervon as Director of Sales for Strategic Accounts effective Monday, October 5, 2026, reporting to SVP of Industrial and Commercial Sales, Jeff Campbell. Carlson brings over 27 years of power tool and outdoor product key account management experience to Chervon. A graduate of Bemidji State University in Bemidji, Minnesota; Carlson launched his career at Makita Power Tools in 1999. He progressed through a series of positions at Makita over the subsequent 10 years. In 2009, Carlson joined TTI/Milwaukee as a Senior National Account Manager. His career flourished as he was promoted through a series of increasingly responsible positions building and managing strategic key account business for TTI/Milwaukee. "Carlson is highly regarded in his ability to not only build the business but also to mentor, train and develop his people," SVP Campbell said. "His extensive experience at building store level and E-Commerce growth makes him a highly valuable addition to Chervon." "It is clear that Chervon shares my maniacal focus on building store level partnerships and end user demand," said Carlson. "I am incredibly excited to continue my career with Chervon as we build a leadership position in the outdoor power equipment and power tool market." About Chervon Chervon North America is part of a global total solution provider specializing in R&D, manufacturing, testing, sales, and after-sales service of power tools and outdoor power equipment (OPE). Guided by user-centric innovation, the Company operates an integrated business model supported by global sales and distribution networks. Chervon's portfolio includes EGO, FLEX, SKIL, and DEVON, serving industrial, professional, and consumer markets globally. Better Tools. Better World. Chervon is committed to delivering superior products to users worldwide through continuous innovation and strives to become a global leader in power tools and OPE in the lithium-ion, intelligent, and digital era. PR Contact: Corporate Communications: [email protected] SOURCE: Chervon
- Micot's XTL6001 Featured in Two EASD Presentations: MasR/GCGR/GLP-1R Triple-Agonist Mechanism Opens a Differentiated Path Across Metabolic and Renal DiseaseHong Kong, Oct 5, 2026 - At the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), one of the world’s most influential scientific meetings in diabetes and metabolic disease, Micot Pharmaceuticals (02335.HK) presented research on XTL6001, its internally developed long-acting protein candidate and triple receptor agonist targeting GLP-1R, GCGR and MasR. The studies, covering high-quality weight management and chronic kidney disease (CKD)/diabetic kidney disease (DKD), were selected for oral presentation, bringing the Chinese-origin innovative programme onto a leading international scientific platform. From a development perspective, XTL6001 is not designed simply to maximise headline weight loss. By combining the GLP-1R, GCGR and MasR pathways, the programme aims to address weight management, glucose and lipid metabolism, body-composition optimisation and potential renal protection within a single development framework. As the GLP-1 field continues to evolve rapidly, this integrated metabolic–renal approach gives XTL6001 a differentiated profile versus conventional incretin-based therapies and provides a clearer positioning for subsequent global clinical development and potential business development opportunities. From Posters to Oral Presentations: Building International Scientific Visibility EASD and the American Diabetes Association (ADA) Scientific Sessions are among the most prominent international scientific platforms in diabetes and metabolic disease. Research on XTL6001 was first presented in two posters at ADA 2026 in June, followed by two oral presentations at EASD. The progression from posters to oral presentation provided a higher-profile forum for the same development thesis to be presented and discussed with the international scientific community. Conference selection, of course, does not substitute for clinical validation. For an early-stage innovative programme, however, repeated exposure at major international meetings can help increase visibility among clinicians, research institutions and potential industry partners. Notably, XTL6001 presented both weight-management and CKD/DKD research at the same EASD meeting. Obesity care is increasingly moving beyond “weight loss alone” toward broader management of body composition and cardiometabolic, hepatic and renal comorbidities. The ability to deliver benefits beyond weight reduction is therefore becoming an important dimension of next-generation competition. By adding MasR to the GLP-1R/GCGR combination, XTL6001 is designed to incorporate a renal-protection component into its differentiated product profile. Weight Loss, Muscle Preservation and Renal Protection: Differentiation Through a Triple-Target Mechanism According to company disclosures and publicly available scientific data, XTL6001 is a long-acting protein drug candidate and a triple receptor agonist targeting GLP-1R, GCGR and MasR. The programme has completed its Phase I study in China and has received clinical trial authorisation in both China and the United States. In the disclosed Phase I single ascending dose (SAD) study, 25 healthy participants received XTL6001 across a dose range of 37.5–300 mg, with additional participants receiving placebo. The study showed a favourable overall safety and tolerability profile. Dr. Xiangling Wang, Micot Pharma’s Chief Medical Officer (CMO), presented a systematic study comparing XTL6001 The available data also indicate that XTL6001 is designed to deliver benefits beyond the headline weight loss shown on the scale. In preclinical diet-induced obesity (DIO) mouse studies, XTL6001 demonstrated greater weight reduction than semaglutide at equivalent doses and a slower rate of weight regain after treatment discontinuation. At the same dose, and despite overall food intake being comparable to or even higher than that observed with semaglutide, weight reduction was approximately 33% greater, suggesting that the effect may be driven more by increased energy expenditure and fat utilisation than by appetite suppression alone. The studies also showed selective fat loss, restoration of the proportion of muscle mass toward normal levels, a 1.61-fold greater reduction in abdominal fat versus semaglutide, and concurrent improvements in lipid and hepatic parameters, including a reduction in LDL-C of more than 80% (87.2%) and a 90.8% reduction in hepatic triglycerides, with near-complete reversal of hepatic steatosis and normalisation of ALT. These findings point to potential utility in MASH. Importantly, the comparisons with semaglutide were generated primarily in animal studies and should not be interpreted as evidence of superior efficacy in humans. In the renal programme, publicly disclosed studies used multiple animal models of kidney disease. The rationale for the triple-target mechanism can be summarised as follows: GLP-1R primarily supports improvements in metabolism and haemodynamics; GCGR may help protect renal tubules from lipotoxic injury; and MasR is intended to address glomerular structural protection and antifibrotic activity. Together, the three pathways are designed to intervene across metabolic drivers, haemodynamic abnormalities, structural injury and fibrosis in the CKD/DKD disease cascade, rather than acting as a simple combination of independent effects. XTL6001 dose-dependently reduced 24-hour urinary albumin excretion and the urine albumin-to-creatinine ratio (UACR), while improving the glomerular filtration rate (GFR). Across different models, XTL6001 showed dose-dependent reductions in albuminuria: in STZ-induced, uninephrectomised rats, 0.5 mg/kg reduced UACR by 62.9% versus vehicle control and reduced 24-hour urinary albumin by approximately 54.7%; in the alloxan model, the reduction in UACR was approximately three times that seen with finerenone monotherapy; and in a mouse CKD model, 12 mg/kg reduced urinary albumin by 80.2%, with reductions in albuminuria reaching approximately 88% across the three models. The studies also observed reductions in serum creatinine, blood urea nitrogen and serum uric acid. These findings provide further support for the programme’s “weight management–metabolic regulation–albuminuria reduction” rationale. However, the renal benefits remain predominantly preclinical and will need to be validated in randomised controlled studies in patients with CKD/DKD. The Obesity Market Is Moving Into a Multi-Target Era — MasR Gives XTL6001 a Distinct Route The next generation of obesity therapies is already progressing from single-target GLP-1 agents toward GLP-1/GIP dual agonists, GLP-1/GCGR dual agonists and GLP-1/GIP/GCGR triple agonists. Eli Lilly’s retatrutide has advanced into Phase III development, while United Laboratories’ UBT251 is in Phase II, underscoring that “multi-target” activity alone is no longer sufficient to create a durable moat. XTL6001 is differentiated by the fact that its third target is MasR rather than GIPR. According to company disclosures, activation of the MasR pathway is associated with anti-inflammatory and antifibrotic effects, promotion of muscle-protein synthesis, improvement in mitochondrial function and induction of mitochondria-mediated thermogenesis. This gives XTL6001 a development rationale that is more naturally centred on renal protection, proteinuria and broader multi-organ metabolic benefits, rather than on cross-trial comparisons of headline weight-loss efficacy where no head-to-head evidence exists. From a capital-markets and business-development perspective, XTL6001’s successive appearances at ADA and EASD, together with its upcoming presentation of hyperuricaemic nephropathy research at ASN Kidney Week 2026, are helping the programme build continuous visibility across the diabetes, obesity and nephrology communities. Presenting at international scientific meetings is not a transaction in itself, nor can it replace human efficacy data, but it can create additional touchpoints with potential licensing, co-development and regional partners. Ultimately, the asset’s value will depend on whether clinical studies in humans can validate the hypotheses around quality of weight loss, body-composition improvement and renal protection; whether its safety and tolerability profile remains competitive; and whether indications such as CKD/DKD can demonstrate reproducible and clinically translatable benefits. If these elements are progressively validated, XTL6001 could establish a more distinctive global development path in the increasingly crowded GLP-1 landscape through a combined positioning around high-quality weight management, metabolic improvement and potential renal protection.
- Micot's XTL6001 Featured in Two EASD Presentations: MasR/GCGR/GLP-1R Triple-Agonist Mechanism Opens a Differentiated Path Across Metabolic and Renal DiseaseHong Kong, Oct 5, 2026 - At the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), one of the world’s most influential scientific meetings in diabetes and metabolic disease, Micot Pharmaceuticals (02335.HK) presented research on XTL6001, its internally developed long-acting protein candidate and triple receptor agonist targeting GLP-1R, GCGR and MasR. The studies, covering high-quality weight management and chronic kidney disease (CKD)/diabetic kidney disease (DKD), were selected for oral presentation, bringing the Chinese-origin innovative programme onto a leading international scientific platform. From a development perspective, XTL6001 is not designed simply to maximise headline weight loss. By combining the GLP-1R, GCGR and MasR pathways, the programme aims to address weight management, glucose and lipid metabolism, body-composition optimisation and potential renal protection within a single development framework. As the GLP-1 field continues to evolve rapidly, this integrated metabolic–renal approach gives XTL6001 a differentiated profile versus conventional incretin-based therapies and provides a clearer positioning for subsequent global clinical development and potential business development opportunities. From Posters to Oral Presentations: Building International Scientific Visibility EASD and the American Diabetes Association (ADA) Scientific Sessions are among the most prominent international scientific platforms in diabetes and metabolic disease. Research on XTL6001 was first presented in two posters at ADA 2026 in June, followed by two oral presentations at EASD. The progression from posters to oral presentation provided a higher-profile forum for the same development thesis to be presented and discussed with the international scientific community. Conference selection, of course, does not substitute for clinical validation. For an early-stage innovative programme, however, repeated exposure at major international meetings can help increase visibility among clinicians, research institutions and potential industry partners. Notably, XTL6001 presented both weight-management and CKD/DKD research at the same EASD meeting. Obesity care is increasingly moving beyond “weight loss alone” toward broader management of body composition and cardiometabolic, hepatic and renal comorbidities. The ability to deliver benefits beyond weight reduction is therefore becoming an important dimension of next-generation competition. By adding MasR to the GLP-1R/GCGR combination, XTL6001 is designed to incorporate a renal-protection component into its differentiated product profile. Weight Loss, Muscle Preservation and Renal Protection: Differentiation Through a Triple-Target Mechanism According to company disclosures and publicly available scientific data, XTL6001 is a long-acting protein drug candidate and a triple receptor agonist targeting GLP-1R, GCGR and MasR. The programme has completed its Phase I study in China and has received clinical trial authorisation in both China and the United States. In the disclosed Phase I single ascending dose (SAD) study, 25 healthy participants received XTL6001 across a dose range of 37.5–300 mg, with additional participants receiving placebo. The study showed a favourable overall safety and tolerability profile. Dr. Xiangling Wang, Micot Pharma’s Chief Medical Officer (CMO), presented a systematic study comparing XTL6001 The available data also indicate that XTL6001 is designed to deliver benefits beyond the headline weight loss shown on the scale. In preclinical diet-induced obesity (DIO) mouse studies, XTL6001 demonstrated greater weight reduction than semaglutide at equivalent doses and a slower rate of weight regain after treatment discontinuation. At the same dose, and despite overall food intake being comparable to or even higher than that observed with semaglutide, weight reduction was approximately 33% greater, suggesting that the effect may be driven more by increased energy expenditure and fat utilisation than by appetite suppression alone. The studies also showed selective fat loss, restoration of the proportion of muscle mass toward normal levels, a 1.61-fold greater reduction in abdominal fat versus semaglutide, and concurrent improvements in lipid and hepatic parameters, including a reduction in LDL-C of more than 80% (87.2%) and a 90.8% reduction in hepatic triglycerides, with near-complete reversal of hepatic steatosis and normalisation of ALT. These findings point to potential utility in MASH. Importantly, the comparisons with semaglutide were generated primarily in animal studies and should not be interpreted as evidence of superior efficacy in humans. In the renal programme, publicly disclosed studies used multiple animal models of kidney disease. The rationale for the triple-target mechanism can be summarised as follows: GLP-1R primarily supports improvements in metabolism and haemodynamics; GCGR may help protect renal tubules from lipotoxic injury; and MasR is intended to address glomerular structural protection and antifibrotic activity. Together, the three pathways are designed to intervene across metabolic drivers, haemodynamic abnormalities, structural injury and fibrosis in the CKD/DKD disease cascade, rather than acting as a simple combination of independent effects. XTL6001 dose-dependently reduced 24-hour urinary albumin excretion and the urine albumin-to-creatinine ratio (UACR), while improving the glomerular filtration rate (GFR). Across different models, XTL6001 showed dose-dependent reductions in albuminuria: in STZ-induced, uninephrectomised rats, 0.5 mg/kg reduced UACR by 62.9% versus vehicle control and reduced 24-hour urinary albumin by approximately 54.7%; in the alloxan model, the reduction in UACR was approximately three times that seen with finerenone monotherapy; and in a mouse CKD model, 12 mg/kg reduced urinary albumin by 80.2%, with reductions in albuminuria reaching approximately 88% across the three models. The studies also observed reductions in serum creatinine, blood urea nitrogen and serum uric acid. These findings provide further support for the programme’s “weight management–metabolic regulation–albuminuria reduction” rationale. However, the renal benefits remain predominantly preclinical and will need to be validated in randomised controlled studies in patients with CKD/DKD. The Obesity Market Is Moving Into a Multi-Target Era — MasR Gives XTL6001 a Distinct Route The next generation of obesity therapies is already progressing from single-target GLP-1 agents toward GLP-1/GIP dual agonists, GLP-1/GCGR dual agonists and GLP-1/GIP/GCGR triple agonists. Eli Lilly’s retatrutide has advanced into Phase III development, while United Laboratories’ UBT251 is in Phase II, underscoring that “multi-target” activity alone is no longer sufficient to create a durable moat. XTL6001 is differentiated by the fact that its third target is MasR rather than GIPR. According to company disclosures, activation of the MasR pathway is associated with anti-inflammatory and antifibrotic effects, promotion of muscle-protein synthesis, improvement in mitochondrial function and induction of mitochondria-mediated thermogenesis. This gives XTL6001 a development rationale that is more naturally centred on renal protection, proteinuria and broader multi-organ metabolic benefits, rather than on cross-trial comparisons of headline weight-loss efficacy where no head-to-head evidence exists. From a capital-markets and business-development perspective, XTL6001’s successive appearances at ADA and EASD, together with its upcoming presentation of hyperuricaemic nephropathy research at ASN Kidney Week 2026, are helping the programme build continuous visibility across the diabetes, obesity and nephrology communities. Presenting at international scientific meetings is not a transaction in itself, nor can it replace human efficacy data, but it can create additional touchpoints with potential licensing, co-development and regional partners. Ultimately, the asset’s value will depend on whether clinical studies in humans can validate the hypotheses around quality of weight loss, body-composition improvement and renal protection; whether its safety and tolerability profile remains competitive; and whether indications such as CKD/DKD can demonstrate reproducible and clinically translatable benefits. If these elements are progressively validated, XTL6001 could establish a more distinctive global development path in the increasingly crowded GLP-1 landscape through a combined positioning around high-quality weight management, metabolic improvement and potential renal protection.
- International Petroleum Corporation Announces Results of Normal Course Issuer BidInternational Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) is pleased to announce that IPC repurchased a total of 98,397 IPC common shares (ISIN: CA46016U1084) during the period of September 28 to October 2, 2026 under IPC’s previously announced normal course issuer bid / share repurchase program (NCIB).
- GoogleMaking AI training available to UK and Ireland educatorsCompanies: Alphabet Inc.Google's AI tools aim to help educators achieve their teaching goals and provide students with personalized learning experiences.
- SkanskaSkanska to construct new high school in Renton, Washington, USA for USD 110M, about SEK 1.0 billionSkanska has signed a contract with the Renton School District for the new Renton High School project in Renton, Washington, USA. The contract is worth USD 110M, about SEK 1.0 billion, which will be included in the US order bookings for the third...